Soligenix Inc. (NASDAQ: SNGX) Showcases Expanding Rare Disease, Public Health Pipeline in Latest Corporate Presentation
At its core, Soligenix is a late-stage biopharmaceutical company that thrives at the intersection of urgent medical need and scientific innovation. SNGX’s Specialized BioTherapeutics division is anchored by its proprietary HyBryte(TM) (“SGX301”), a novel photodynamic therapy for CTCL. Soligenix’s Public Health Solutions division positions the company as an important contributor to biodefense and emerging infectious disease. Soligenix (NASDAQ: SNGX) has taken a bold step forward…